Preisler H D, Epstein J, Barcos M, Priore R, Raza A, Browman G P, Vogler R, Winton E, Grunwald H, Rai K
Br J Haematol. 1984 Sep;58(1):19-32. doi: 10.1111/j.1365-2141.1984.tb06055.x.
The Leukemia Intergroup Study has treated 110 patients with acute nonlymphocytic leukaemia with 'high dose' cytosine arabinoside remission induction therapy and studied the factors which were related to the outcome of therapy. With respect to death during remission induction therapy, only patient age was of prognostic significance. Treatment failure due to resistant leukaemia was associated with a high pretherapy leukaemic cell mass, the presence of few cells in S phase, and insensitivity of DNA synthesis to cytosine arabinoside. If, after 6 d of therapy, more than 40% of the marrow cells were leukaemic, the patient almost invariably failed to enter complete remission because of persistent leukaemia. Simultaneous consideration of the pretherapy labelling index and the per cent abnormal cells in the day 6 marrow permitted a distinction to be made between almost all patients who would enter remission or fail therapy because of persistent leukaemia.
白血病协作组研究采用“大剂量”阿糖胞苷缓解诱导疗法治疗了110例急性非淋巴细胞白血病患者，并研究了与治疗结果相关的因素。关于缓解诱导治疗期间的死亡，只有患者年龄具有预后意义。因耐药白血病导致的治疗失败与治疗前白血病细胞数量多、S期细胞数量少以及DNA合成对阿糖胞苷不敏感有关。如果治疗6天后，超过40%的骨髓细胞为白血病细胞，患者几乎总是因白血病持续存在而无法进入完全缓解。同时考虑治疗前标记指数和第6天骨髓中异常细胞的百分比，可以区分几乎所有将进入缓解或因白血病持续存在而治疗失败的患者。
